Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maren Knoedler

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Oncology|March 27, 2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenibKaja Zimmermann, Alexander Schmittel, Ursula Steiner, et al.
European Journal of Immunology|October 26, 2007
CMV-specific central memory T cells reside in bone marrowAnne Letsch, Maren Knoedler, Il-Kang Na, et al.
JAMA Network Open|February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With CancerChiara A Cella, Maren Knoedler, Marcia Hall, et al.
Oncology Research and Treatment|December 16, 2021
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID TrialUte Goerling, Thomas Gauler, Andreas Dietz, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Oncology|March 27, 2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenibKaja Zimmermann, Alexander Schmittel, Ursula Steiner, et al.
European Journal of Immunology|October 26, 2007
CMV-specific central memory T cells reside in bone marrowAnne Letsch, Maren Knoedler, Il-Kang Na, et al.
JAMA Network Open|February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With CancerChiara A Cella, Maren Knoedler, Marcia Hall, et al.
Oncology Research and Treatment|December 16, 2021
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID TrialUte Goerling, Thomas Gauler, Andreas Dietz, et al.
Pageof 1